FDA 483 - Optum Infusion Services 308, LLC - March 18, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
This FDA Form 483 was issued to Optum Infusion Services 308, LLC, a producer of sterile drug products, located at 2555 W Fairview St Ste 104 Bldg D, Chandler, AZ, following an inspection from March 8-18, 2022. William J. Kottmer, General Manager, was the recipient.
Six observations were noted:
1. **Inadequate product evaluation for microbial contamination:** The firm failed to assess the impact on sterile drug products after finding bacterial/fungal growth (Brevibacterium, Micrococcus, Coagulase Negative Staphylococcus, Aspergillus, Alternaria, Paenibacillus species) in ISO-5 and ISO-7 areas on multiple dates (November 22, 2021; August 16, 2021; May 4, 2021). Products produced during these contamination periods were not evaluated for potential impact.
2. **Improper personnel aseptic technique:** Technicians were observed touching non-ISO 5 surfaces with gloved hands and then engaging in aseptic processing without sanitizing or changing gloves. Examples include opening sterile bags in ISO-7 and then touching the Direct Compounding Area in ISO-5 without re-sanitizing, and touching dirty mop pads then other surfaces without glove changes/sanitization.
3. **Exposed hair during aseptic processing:** Technicians
ID · 9ab6ac46-4365-4855-b792-3dffeb66c2b0